Morgan Stanley Cytokinetics Inc Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Cytokinetics Inc stock. As of the latest transaction made, Morgan Stanley holds 1,118,080 shares of CYTK stock, worth $66.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,118,080

Previous 1,011,745 10.51%

Holding current value

$66.4 Million

Previous $40.7 Million 9.15%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$29.84 - $42.92 $3.17 Million - $4.56 Million	106,335 Added 10.51%	1,118,080 $36.9 Million
Q1 2025 May 15, 2025	SELL	$40.19 - $51.12 $9.7 Million - $12.3 Million	-241,243 Reduced 19.25%	1,011,745 $40.7 Million
Q4 2024 Feb 14, 2025	BUY	$46.36 - $58.62 $3.92 Million - $4.96 Million	84,616 Added 7.24%	1,252,988 $58.9 Million
Q3 2024 May 14, 2025	BUY	$51.22 - $60.16 $3.21 Million - $3.77 Million	62,698 Added 5.67%	1,168,372 $61.7 Million
Q3 2024 Nov 14, 2024	BUY	$51.22 - $60.16 $3.21 Million - $3.77 Million	62,698 Added 5.67%	1,168,372 $61.7 Million
Q2 2024 May 14, 2025	SELL	$47.86 - $75.05 $7.05 Million - $11.1 Million	-147,314 Reduced 11.76%	1,105,674 $59.9 Million
Q2 2024 Oct 17, 2024	BUY	$47.86 - $75.05 $7.22 Million - $11.3 Million	150,816 Added 15.79%	1,105,674 $59.9 Million
Q2 2024 Aug 14, 2024	BUY	$47.86 - $75.05 $7.22 Million - $11.3 Million	150,816 Added 15.79%	1,105,674 $59.9 Million
Q1 2024 Oct 17, 2024	SELL	$63.75 - $108.06 $9.61 Million - $16.3 Million	-150,816 Reduced 13.64%	954,858 $66.9 Million
Q1 2024 Aug 16, 2024	SELL	$63.75 - $108.06 $92.2 Million - $156 Million	-1,446,724 Reduced 60.24%	954,858 $66.9 Million
Q1 2024 May 15, 2024	SELL	$63.75 - $108.06 $92.2 Million - $156 Million	-1,446,724 Reduced 60.24%	954,858 $66.9 Million
Q4 2023 Aug 16, 2024	BUY	$26.88 - $83.49 $34.8 Million - $108 Million	1,295,908 Added 117.21%	2,401,582 $201 Million
Q4 2023 Feb 13, 2024	BUY	$26.88 - $83.49 $36.3 Million - $113 Million	1,349,376 Added 128.24%	2,401,582 $201 Million
Q3 2023 Nov 15, 2023	BUY	$29.46 - $36.61 $4.24 Million - $5.27 Million	143,955 Added 15.85%	1,052,206 $31 Million
Q2 2023 Aug 14, 2023	BUY	$32.62 - $40.75 $3.13 Million - $3.91 Million	96,007 Added 11.82%	908,251 $29.6 Million
Q1 2023 May 15, 2023	SELL	$33.36 - $45.71 $15.1 Million - $20.7 Million	-453,618 Reduced 35.83%	812,244 $28.6 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $5.17 Million - $7.39 Million	-144,504 Reduced 10.25%	1,265,862 $58 Million
Q3 2022 Nov 14, 2022	SELL	$38.54 - $54.52 $3.46 Million - $4.89 Million	-89,739 Reduced 5.98%	1,410,366 $68.3 Million
Q2 2022 Oct 27, 2022	BUY	$33.93 - $48.92 $11.2 Million - $16.1 Million	329,286 Added 28.12%	1,500,105 $58.9 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $11.2 Million - $16.1 Million	329,286 Added 28.12%	1,500,105 $58.9 Million
Q1 2022 Oct 27, 2022	SELL	$29.74 - $46.0 $9.79 Million - $15.1 Million	-329,286 Reduced 21.95%	1,170,819 $43.1 Million
Q1 2022 May 13, 2022	BUY	$29.74 - $46.0 $8.9 Million - $13.8 Million	299,157 Added 34.32%	1,170,819 $43.1 Million
Q4 2021 Feb 14, 2022	BUY	$34.35 - $46.38 $1.06 Million - $1.43 Million	30,738 Added 3.66%	871,662 $39.7 Million
Q3 2021 Nov 15, 2021	BUY	$18.54 - $35.74 $15.6 Million - $30.1 Million	840,924 New	840,924 $30.1 Million

Others Institutions Holding CYTK

# of Institutions

380

Shares Held

129M

Call Options Held

3.62M

Put Options Held

1.14M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $5.59B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account